Hartmut Kristeleit

928 total citations
19 papers, 229 citations indexed

About

Hartmut Kristeleit is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hartmut Kristeleit has authored 19 papers receiving a total of 229 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hartmut Kristeleit's work include HER2/EGFR in Cancer Research (7 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Hartmut Kristeleit is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Hartmut Kristeleit collaborates with scholars based in United Kingdom, United States and Australia. Hartmut Kristeleit's co-authors include J. Blake Bartlett, Steve Nicholson, Ian Clarke, David Stirling, H. Pandha, Angus Dalgleish, George W. Muller, Jerome B. Zeldis, Keith Dredge and Deborah Enting and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Hartmut Kristeleit

18 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hartmut Kristeleit United Kingdom 7 119 88 73 69 40 19 229
Claudia A.M. Stege Netherlands 8 110 0.9× 95 1.1× 126 1.7× 36 0.5× 19 0.5× 15 239
Roberta Gonella Italy 10 115 1.0× 61 0.7× 80 1.1× 36 0.5× 18 0.5× 17 257
Robin Meng United States 5 118 1.0× 65 0.7× 73 1.0× 30 0.4× 31 0.8× 10 234
Danko Martincic United States 10 71 0.6× 84 1.0× 113 1.5× 55 0.8× 65 1.6× 20 238
Sihem Kaaki France 6 86 0.7× 72 0.8× 39 0.5× 46 0.7× 22 0.6× 8 181
Adam del Corral United States 4 82 0.7× 138 1.6× 219 3.0× 82 1.2× 70 1.8× 5 332
Daniel Morillo Spain 9 141 1.2× 98 1.1× 152 2.1× 18 0.3× 32 0.8× 30 275
Sunil Gandhi United States 6 84 0.7× 132 1.5× 77 1.1× 53 0.8× 35 0.9× 8 232
Xing Sun United States 7 64 0.5× 131 1.5× 67 0.9× 116 1.7× 10 0.3× 10 306
Vallari Shah United Kingdom 8 126 1.1× 141 1.6× 172 2.4× 13 0.2× 40 1.0× 14 297

Countries citing papers authored by Hartmut Kristeleit

Since Specialization
Citations

This map shows the geographic impact of Hartmut Kristeleit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hartmut Kristeleit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hartmut Kristeleit more than expected).

Fields of papers citing papers by Hartmut Kristeleit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hartmut Kristeleit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hartmut Kristeleit. The network helps show where Hartmut Kristeleit may publish in the future.

Co-authorship network of co-authors of Hartmut Kristeleit

This figure shows the co-authorship network connecting the top 25 collaborators of Hartmut Kristeleit. A scholar is included among the top collaborators of Hartmut Kristeleit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hartmut Kristeleit. Hartmut Kristeleit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Khanbhai, Mustafa, Vivek Patkar, Danny Ruta, et al.. (2024). Breast Cancer Decision Support: Expert Systems vs. Machine Learning – have we thrown the baby out with the bathwater?. Medical Research Archives. 12(12). 1 indexed citations
2.
Kristeleit, Hartmut, Vivek Misra, Mark Baxter, et al.. (2022). Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study. Oncology. 100(12). 666–673. 2 indexed citations
3.
Kenny, Laura, Mark Beresford, Ian Brown, Vivek Misra, & Hartmut Kristeleit. (2022). Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. European Journal of Cancer Care. 31(6). e13747–e13747. 2 indexed citations
4.
Battisti, Nicolò Matteo Luca, Belinda Kingston, Judy King, et al.. (2019). Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Research and Treatment. 174(3). 731–740. 15 indexed citations
5.
Battisti, Nicolò Matteo Luca, Belinda Kingston, James P. King, et al.. (2019). Abstract P6-18-23: Palbociclib and endocrine therapy in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: The UK compassionate access program experience. Cancer Research. 79(4_Supplement). P6–18. 1 indexed citations
6.
Thủy, Nguyễn Minh, Liliane Robillard, Thomas C. Harding, et al.. (2019). Abstract 3888: Intracranial evaluation of the in vivo pharmacokinetics, brain distribution, and efficacy of rucaparib inBRCA-mutant, triple-negative breast cancer. 3888–3888. 2 indexed citations
7.
Nguyen, Minh, Liliane Robillard, Thomas C. Harding, et al.. (2019). Abstract 3888: Intracranial evaluation of the in vivo pharmacokinetics, brain distribution, and efficacy of rucaparib in BRCA-mutant, triple-negative breast cancer. Cancer Research. 79(13_Supplement). 3888–3888. 9 indexed citations
8.
Azad, Gurdip, Angela Swampillai, Paul Bassett, et al.. (2018). Measuring validity of response assessment in bone predominant metastatic breast cancer based on clinico-radiological evaluation: An Inter-observer study.. Journal of Clinical Oncology. 36(15_suppl). e13055–e13055. 1 indexed citations
9.
Azad, Gurdip, Benjamin Taylor, Adrian J. Green, et al.. (2018). Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. European Journal of Nuclear Medicine and Molecular Imaging. 46(4). 821–830. 28 indexed citations
10.
Jafri, Mariam, Hartmut Kristeleit, Vivek Misra, et al.. (2018). Eribulin in metastatic breast cancer the UK experience: A multi-centre retrospective 577 patient study. Annals of Oncology. 29. viii100–viii100. 1 indexed citations
11.
12.
13.
Kristeleit, Hartmut, Marina Parton, Mark Beresford, et al.. (2016). Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Targeted Oncology. 11(5). 579–591. 6 indexed citations
14.
Molife, L. Rhoda, Sarah Maria Rudman, Salma Alam, et al.. (2013). Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemotherapy and Pharmacology. 72(6). 1213–1222. 15 indexed citations
15.
16.
Lal, Rohit, Deborah Enting, & Hartmut Kristeleit. (2011). Systemic treatment of non-small-cell lung cancer. European Journal of Cancer. 47. S375–S377. 7 indexed citations
17.
Kristeleit, Hartmut, et al.. (2011). Basic science of lung cancer. European Journal of Cancer. 47. S319–S321. 3 indexed citations
18.
Kristeleit, Hartmut. (2005). IGN-311. Igeneon.. PubMed. 6(12). 1272–9. 4 indexed citations
19.
Bartlett, J. Blake, Ian Clarke, Keith Dredge, et al.. (2004). Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. British Journal of Cancer. 90(5). 955–961. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia A.M. Stege Breakdown of academic impact, for papers by Roberta Gonella Breakdown of academic impact, for papers by Robin Meng Breakdown of academic impact, for papers by Danko Martincic Breakdown of academic impact, for papers by Sihem Kaaki Breakdown of academic impact, for papers by Adam del Corral Breakdown of academic impact, for papers by Daniel Morillo Breakdown of academic impact, for papers by Sunil Gandhi Breakdown of academic impact, for papers by Xing Sun Breakdown of academic impact, for papers by Vallari Shah
Rankless by CCL
2026